Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Address: 5 Leeuwkop Road
Sunninghill
Gauteng
2157,South Africa
Tel: +27 11 797 6000
Web: http://www.astrazeneca.com/About-Us/Worldwide-locations/Country/South-Africa
For patients and physicians, we provide medicines for some of the world’s most serious diseases. For the people who pay for healthcare, we work to make sure that our medicines offer real value for money. For our employees, we provide a culture in which they can feel appreciated, energised and rewarded for their contribution. For our shareholders, we aim to deliver value through our continued focus on innovation and running our business efficiently. For the wider community, we want to be valued for the contribution our medicines can make to society and trusted for the way in which we do business.
We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health.
AstraZeneca South Africa is a biopharmaceutical company.
AstraZeneca South Africa discovers, develops, manufactures and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
